Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization.
about
Mouse models for human otitis mediaSerum resistance in Haemophilus ducreyi requires outer membrane protein DsrAComprehensive antigen screening identifies Moraxella catarrhalis proteins that induce protection in a mouse pulmonary clearance modelNeedleless vaccine delivery using micro-shock wavesEnhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins.Mapping of a protective epitope of the CopB outer membrane protein of Moraxella catarrhalisSynthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.Phenotypic effect of isogenic uspA1 and uspA2 mutations on Moraxella catarrhalis 035E.Isolation and characterization of two proteins from Moraxella catarrhalis that bear a common epitopeSynthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model.Moraxella catarrhalis: from emerging to established pathogen.Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art reviewCharacterization of the Moraxella catarrhalis uspA1 and uspA2 genes and their encoded products.Analysis of antigenic structure and human immune response to outer membrane protein CD of Moraxella catarrhalisAntigenic structure of outer membrane protein E of Moraxella catarrhalis and construction and characterization of mutants.Intranasal immunization of the combined lipooligosaccharide conjugates protects mice from the challenges with three serotypes of Moraxella catarrhalis.Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine.Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalis.A protective epitope of Moraxella catarrhalis is encoded by two different genesMoraxella catarrhalis outer membrane protein CD elicits antibodies that inhibit CD binding to human mucin and enhance pulmonary clearance of M. catarrhalis in a mouse modelVaccine targets against Moraxella catarrhalis.Mining the Moraxella catarrhalis genome: identification of potential vaccine antigens expressed during human infectionMouse models as a tool to unravel the genetic basis for human otitis media.Characterization of proteins Msp22 and Msp75 as vaccine antigens of Moraxella catarrhalis.The UspA1 protein and a second type of UspA2 protein mediate adherence of Moraxella catarrhalis to human epithelial cells in vitro.The levels and bactericidal capacity of antibodies directed against the UspA1 and UspA2 outer membrane proteins of Moraxella (Branhamella) catarrhalis in adults and children.Analysis of the immunological responses to transferrin and lactoferrin receptor proteins from Moraxella catarrhalis.Immune responses to specific antigens of Streptococcus pneumoniae and Moraxella catarrhalis in the respiratory tract.A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: an update on current progress and challenges.Passive immunization by recombinant ferric enterobactin protein (FepA) from Escherichia coli O157.Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine modelMapping protective regions on a three-dimensional model of the Moraxella catarrhalis vaccine antigen, Oligopeptide Permease A.
P2860
Q27491017-7025318C-B850-4786-A654-19A4F445E519Q28144889-8EC9EE46-2A6B-4F93-8DB5-6E317F1CB0C9Q28382833-D7CC6A25-0FE4-4F51-B83D-66DCEE475EEAQ30501618-BE89BEC9-1226-49C9-86F2-3876E1E47FFDQ33597864-DCB8D8B7-2FE2-4B16-B0A8-8CD72B2D4C52Q33750175-F948631E-E2DD-45AE-BF4E-466BC546FC15Q33753424-3D97FFCE-7079-4E7B-979D-E7679D5DC979Q33756099-E861AA99-E439-4CC6-8C7F-05F9466D6D33Q33762570-5588A727-65D6-44ED-BCB6-0D2C1753264DQ33768943-76CAB9B1-7CE6-47A3-84FE-45CCAA6E308CQ33795071-FC6E9467-44D0-43C1-A467-84C6DEDA889EQ33906182-1D9AB40A-3AD7-4EE8-93A7-01EB1CA9D390Q33975684-FCDD4353-1C56-4571-82A8-503B72F12611Q33992458-697FD85D-9F3E-4A4C-85DC-E16E70C3260BQ34001748-3CF69F93-75B1-4A22-9960-D1520F254B7DQ34004983-DCEC390A-C137-4807-AB5A-0D6338F23E49Q34117703-E01DE5A0-13AB-4174-90D8-1D2919F5CCEEQ34183386-A68C0CA7-2587-401B-8A65-B05E9C46BBB2Q35029651-B9BD3F5F-B8C7-4B10-8655-CC1690275576Q35557302-640DE250-2F71-4BAA-8043-B89D31594ECBQ35913382-E2DA4D97-115A-464C-9709-029A38792CEDQ36483998-5719ABAE-CF44-4BA2-BBF0-5A115A460F51Q36539535-D95D1E91-D602-42B0-A952-3AA58D258140Q36569492-F94C03BC-CD72-4757-9C8A-7D63838E4DB0Q37441243-65F61B9F-58E2-4E46-873C-1D5169123099Q39499324-ADF16384-6601-4EB1-9169-A166E027F8D4Q39510092-39ABC11D-501C-4644-81BA-9B62224C92CBQ39511128-AC6E030B-31AE-4DC9-8CDF-76E4EBBBF73BQ39514732-2A4F9923-7FA1-46CC-A5AA-0818DB6F2039Q40074756-7BE28A97-04C7-4FD5-A537-0FD7E7601312Q41462185-DA3CE3FD-82FB-4A6D-94E7-2B1E47B3601BQ41836038-276DBB0F-D989-4E12-A8F9-5517E6B54EAEQ47332587-7CE5EF7F-48DB-454E-922B-E4E80E010FAD
P2860
Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Evaluation of purified UspA fr ...... del after active immunization.
@ast
Evaluation of purified UspA fr ...... del after active immunization.
@en
type
label
Evaluation of purified UspA fr ...... del after active immunization.
@ast
Evaluation of purified UspA fr ...... del after active immunization.
@en
prefLabel
Evaluation of purified UspA fr ...... del after active immunization.
@ast
Evaluation of purified UspA fr ...... del after active immunization.
@en
P2093
P2860
P1476
Evaluation of purified UspA fr ...... odel after active immunization
@en
P2093
Eldridge J
McMichael JC
VanDerMeid KR
P2860
P304
P407
P577
1996-06-01T00:00:00Z